Literature DB >> 24008289

Metastatic volume: an old oncologic concept and a new prognostic factor for stage IV melanoma patients.

V Panasiti1, M Curzio, V Roberti, P Lieto, V Devirgiliis, S Gobbi, A Naspi, R Coppola, T Lopez, N di Meo, A Gatti, G Trevisan, P Londei, S Calvieri.   

Abstract

BACKGROUND: The last melanoma staging system of the 2009 American Joint Committee on Cancer takes into account, for stage IV disease, the serum levels of lactate dehydrogenase (LDH) and the site of distant metastases.
OBJECTIVE: Our aim was to compare the significance of metastatic volume, as evaluated at the time of stage IV melanoma diagnosis, with other clinical predictors of prognosis.
METHODS: We conducted a retrospective multicentric study. To establish which variables were statistically correlated both with death and survival time, contingency tables were evaluated. The overall survival curves were compared using the Kaplan-Meier method.
RESULTS: Metastatic volume and number of affected organs were statistically related to death. In detail, patients with a metastatic volume >15 cm(3) had a worse prognosis than those with a volume lower than this value (survival probability at 60 months: 6.8 vs. 40.9%, respectively). The Kaplan-Meier method confirmed that survival time was significantly related to the site(s) of metastases, to elevated LDH serum levels and to melanoma stage according to the latest system.
CONCLUSION: Our results suggest that metastatic volume may be considered as a useful prognostic factor for survival among melanoma patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24008289     DOI: 10.1159/000351713

Source DB:  PubMed          Journal:  Dermatology        ISSN: 1018-8665            Impact factor:   5.366


  4 in total

1.  TLR7 Gln11Leu single nucleotide polymorphism and susceptibility to cutaneous melanoma.

Authors:  Lisa Elefanti; Giorgia Sacco; Camilla Stagni; Marco Rastrelli; Chiara Menin; Irene Russo; Mauro Alaibac
Journal:  Oncol Lett       Date:  2016-05-16       Impact factor: 2.967

2.  Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.

Authors:  Mahrukh M Syeda; Jennifer M Wiggins; Broderick C Corless; Georgina V Long; Keith T Flaherty; Dirk Schadendorf; Paul D Nathan; Caroline Robert; Antoni Ribas; Michael A Davies; Jean Jacques Grob; Eduard Gasal; Matthew Squires; Mahtab Marker; James Garrett; Jan C Brase; David Polsky
Journal:  Lancet Oncol       Date:  2021-02-12       Impact factor: 41.316

3.  Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.

Authors:  Carlos R Figueiredo; Ricardo A Azevedo; Sasha Mousdell; Pedro T Resende-Lara; Lucy Ireland; Almudena Santos; Natalia Girola; Rodrigo L O R Cunha; Michael C Schmid; Luciano Polonelli; Luiz R Travassos; Ainhoa Mielgo
Journal:  Front Immunol       Date:  2018-05-23       Impact factor: 7.561

4.  Computer-assisted measurement of primary tumor area is prognostic of recurrence-free survival in stage IB melanoma patients.

Authors:  Brooke E Rosenbaum; Christine N Schafer; Sung Won Han; Iman Osman; Hua Zhong; Nooshin Brinster
Journal:  Mod Pathol       Date:  2017-07-21       Impact factor: 7.842

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.